Nathalie Adda - Dec 1, 2021 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Sr. VP & Chief Medical Officer
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Dec 1, 2021
Transactions value $
-$629,656
Form type
4
Date filed
12/3/2021, 06:02 PM
Previous filing
Nov 23, 2021
Next filing
Jan 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Tax liability -$73.8K -842 -2.5% $87.68 32.9K Dec 1, 2021 Direct F1
transaction ENTA Common Stock Options Exercise $380K +8.75K +26.59% $43.46 41.7K Dec 1, 2021 Direct
transaction ENTA Common Stock Options Exercise $232K +4.77K +11.46% $48.52 46.4K Dec 1, 2021 Direct
transaction ENTA Common Stock Sale -$135K -1.59K -3.42% $84.81 44.8K Dec 1, 2021 Direct F2, F3
transaction ENTA Common Stock Sale -$490K -5.74K -12.79% $85.49 39.1K Dec 1, 2021 Direct F2, F4
transaction ENTA Common Stock Sale -$233K -2.7K -6.91% $86.45 36.4K Dec 1, 2021 Direct F2, F5
transaction ENTA Common Stock Sale -$131K -1.5K -4.12% $87.60 34.9K Dec 1, 2021 Direct F2, F6
transaction ENTA Common Stock Sale -$79.5K -900 -2.58% $88.31 34K Dec 1, 2021 Direct F2, F7
transaction ENTA Common Stock Sale -$80.3K -899 -2.64% $89.33 33.1K Dec 1, 2021 Direct F2, F8
transaction ENTA Common Stock Sale -$18.1K -201 -0.61% $90.17 32.9K Dec 1, 2021 Direct F2, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -8.75K -15.98% $0.00 46K Dec 1, 2021 Common Stock 8.75K $43.46 Direct F10
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -4.77K -34.21% $0.00 9.18K Dec 1, 2021 Common Stock 4.77K $48.52 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.43 to $84.98, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.98, inclusive.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.03 to $86.91, inclusive.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $87.23 to $87.92, inclusive.
F7 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $88.01 to $88.90, inclusive.
F8 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $89.02 to $89.88, inclusive.
F9 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.25, inclusive.
F10 100% of the shares subject to the option are fully vested and exercisable.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 9 above.